Published in Trials on June 25, 2007
Standardising outcomes for clinical trials and systematic reviews. Trials (2007) 3.76
Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists. BMJ (2011) 3.50
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci (2009) 1.57
Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest (2013) 1.38
Emerging inflammatory bowel disease in saudi outpatients: a report of 693 cases. Saudi J Gastroenterol (2013) 1.14
The Importance of Integration of Stakeholder Views in Core Outcome Set Development: Otitis Media with Effusion in Children with Cleft Palate. PLoS One (2015) 1.03
The natural history of conducting and reporting clinical trials: interviews with trialists. Trials (2015) 0.90
Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab. Gastroenterol Rep (Oxf) (2014) 0.88
Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol (2012) 0.86
Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol (2012) 0.84
Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut (2013) 0.83
Voting for image scoring and assessment (VISA)--theory and application of a 2 + 1 reader algorithm to improve accuracy of imaging endpoints in clinical trials. BMC Med Imaging (2015) 0.80
IBS and IBD - separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol (2016) 0.79
Fast-track drug approval in inflammatory bowel diseases. Ann Gastroenterol (2016) 0.77
How to read a clinical trial paper: a lesson in basic trial statistics. Gastroenterol Hepatol (N Y) (2012) 0.75
Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. BMJ Open (2017) 0.75
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res (2017) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J (1955) 19.22
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med (1987) 7.73
VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J (1964) 7.02
Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med (1994) 6.05
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
A simple clinical colitis activity index. Gut (1998) 4.35
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ (1989) 4.13
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut (2000) 3.69
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med (2005) 3.56
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology (1987) 3.35
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol (2002) 3.31
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology (1994) 3.22
Microscopic activity in ulcerative colitis: what does it mean? Gut (1991) 2.43
An analysis of the reliability of detection and diagnostic value of various pathological features in Crohn's disease and ulcerative colitis. Gut (1973) 2.21
Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut (1986) 2.17
Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci (1982) 1.85
Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology (Oxford) (2005) 1.84
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut (2005) 1.72
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol (1993) 1.61
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol (2005) 1.59
Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. Scand J Gastroenterol (1999) 1.33
What is colitis? Statistical approach to distinguishing clinically important inflammatory change in rectal biopsy specimens. J Clin Pathol (1988) 1.23
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2006) 1.20
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology (1998) 1.18
Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol (2004) 1.09
How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop. J Clin Pathol (2002) 1.05
Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity. Scand J Gastroenterol (2000) 1.01
Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol (1998) 0.89
Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther (1995) 0.88
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med (2009) 35.37
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009) 34.99
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA (2004) 23.87
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 22.34
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol (2009) 17.92
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
CONSORT statement: extension to cluster randomised trials. BMJ (2004) 16.50
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med (2010) 16.11
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med (2008) 13.87
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (2010) 12.98
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA (2006) 11.87
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol (2009) 11.80
Epidemiology and reporting characteristics of systematic reviews. PLoS Med (2007) 11.51
Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med (2004) 11.47
Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust (2006) 11.40
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ (2004) 10.75
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ (2008) 9.98
Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst (2005) 9.38
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med (2010) 9.30
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (2013) 9.01
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med (2007) 8.77
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
Developing core outcome sets for clinical trials: issues to consider. Trials (2012) 8.39
Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med (2006) 8.25
SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med (2013) 8.21
Comparison of registered and published primary outcomes in randomized controlled trials. JAMA (2009) 7.89
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One (2009) 7.60
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ (2014) 7.55
Consort 2010 statement: extension to cluster randomised trials. BMJ (2012) 7.47
Guidance for developers of health research reporting guidelines. PLoS Med (2010) 7.43
Diagnostic tests 4: likelihood ratios. BMJ (2004) 7.33
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 7.04
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med (2010) 6.88
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ (2003) 6.61
Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet (2002) 6.61
Epidemiology and reporting of randomised trials published in PubMed journals. Lancet (2005) 6.55
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol (2005) 6.31
The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol (2013) 5.93
CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med (2008) 5.85
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ (2010) 5.70
The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ (2010) 5.58
No surgical innovation without evaluation: the IDEAL recommendations. Lancet (2009) 5.57
Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat (2007) 5.52
An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ (2009) 5.45
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ (2005) 5.36
The design of simulation studies in medical statistics. Stat Med (2006) 5.30
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology (2007) 5.12
Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA (2013) 4.98
Ghost authorship in industry-initiated randomised trials. PLoS Med (2007) 4.95
Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut (2011) 4.79
Quantification of the completeness of follow-up. Lancet (2002) 4.77
Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA (2012) 4.73
Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA (2010) 4.56
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
Prognosis and prognostic research: what, why, and how? BMJ (2009) 4.46
An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ (2010) 4.46
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med (2009) 4.43
REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat (2006) 4.42
Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ (2009) 4.38
Prognosis and prognostic research: Developing a prognostic model. BMJ (2009) 4.38
Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev (2012) 4.36
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med (2015) 4.32
Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol (2002) 4.30
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med (2007) 4.29
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials (2010) 4.28
CONSORT for reporting randomised trials in journal and conference abstracts. Lancet (2008) 4.20
Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors'. Trials (2008) 4.17
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J (2002) 3.96
CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 3.96
Developing a prognostic model in the presence of missing data: an ovarian cancer case study. J Clin Epidemiol (2003) 3.90
CONSORT 2010 changes and testing blindness in RCTs. Lancet (2010) 3.68
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ (2009) 3.65
Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med (2010) 3.63
Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med (2008) 3.63
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg (2011) 3.57
Ten steps towards improving prognosis research. BMJ (2009) 3.44